Request for issuance of authorization and consent to use federal rights in three patents to supply enzalutamide to patients in government programs

This is a PDF copy of the letter June 13, 2025 Robert F. Kennedy, Jr. Secretary U.S. Department of Health and Human Services 200 Independence Ave SW, Washington, DC 20201 RE: Request for issuance of authorization and consent to use… Continue Reading

Bangladesh, Brazil, Colombia, India, and Pakistan to convene WTO TRIPS Council Side event – 30 Years of TRIPS: Expectations and Concerns of Developing Countries

πŸ“… Date & Time: March 19, 2025 – 1:00-5:00 PM (CET) πŸ“ Location: WTO, Room S1 (Hybrid Format) πŸ”— Zoom Link: https://worldtradeorganization.zoom.us/j/81973510375?pwd=UdaNgKZIdjb8brcbo1GyRVePPn6K6W.1 πŸ†” Meeting ID: 819 7351 0375 | Passcode: 190305 πŸ“Œ If you wish to attend online, no previous… Continue Reading

KEI Submissions to 2025 Special 301 Review

Annually, the Office of the United States Trade Representative spearheads the Special 301 review process, whose goal is to produce a report that names-and-shames countries that have committed perceived offenses against intellectual property rights. The USTR solicits written comments from… Continue Reading

EB156: KEI statement on the rare diseases decision under agenda item 6 (Universal health coverage)

On Wednesday morning, 5 February 2025, Knowledge Ecology International (KEI) delivered the following statement on the rare diseases decision under agenda item 6 on Universal Health Coverage. Item 6 Universal health coverage Knowledge Ecology International A challenge for the rare… Continue Reading

INB11: Statement of Knowledge Ecology International (KEI) – Legal architecture of the proposal for the WHO Pandemic Agreement

On Monday afternoon, 9 September 2024, Knowledge Ecology International (KEI) delivered this statement on the legal architecture of the proposal for the WHO Pandemic Agreement. KEI has an open mind regarding the appropriate nature of the instrument or instruments for… Continue Reading

PAF v AbbVie excessive pricing case the Netherlands

On 14 May 2024, the Pharmaceutical Accountability Foundation (PAF) had their first hearing in their case against Abbvie at the Amsterdam District Court. The case concerns Abbvie’s pricing practices for its blockbuster drug Humira (adalimumab), one of the world’s best-selling… Continue Reading